Monthly Upstream

Why Upstream and Why Now?

Moving upstream is not simply a health system aspiration; it is an economic and industry imperative.

Ireland’s Medtech sector is uniquely positioned as both a global exporter and a living testbed for upstream innovation, giving it strategic leverage to lead in prevention-focused healthcare. International and Irish evidence demonstrates that preventive action delivers strong returns:

• A national diabetes prevention programme could generate a 1.6x ROI and reduce disease incidence by up to 4.6% (Pierse et al., 2021).
• If preventable risk factors were systematically addressed, Ireland could gain an average of 2.1 additional years of life expectancy (OECD, 2024).
• Up to 70% of chronic disease spending can be avoided through earlier intervention and effective management (Department of Health, 2023).

This report complements detailed economic analysis from the WiFOR Institute (2025) on Chronic Limb-Threatening Ischaemia (CLTI), which showed that early Medtech intervention could reduce major amputations by 40% and deliver returns of €1.60–€2.10 for every euro invested. That study provides the quantitative foundation for the broader argument advanced here: that prevention-aligned medtech is both a public good and a commercial opportunity.